Prague Med. Rep. 2020, 121, 5-24

https://doi.org/10.14712/23362936.2020.1

Buspirone-associated Movement Disorder: A Literature Review

Jamir Pitton Rissardo, Ana Letícia Fornari Caprara

Department of Medicine and Department of Neurology, Federal University of Santa Maria, Santa Maria, Brasil

Received December 29, 2019
Accepted February 17, 2020

References

1. Ables, A. Z., Nagubilli, R. (2010) Prevention, recognition, and management of serotonin syndrome. Am. Fam. Physician 81(9), 1139–1142.
2. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders (DSM-5). American Psychiatric Publishing, Arlington.
3. Atoji, Y., Sarkar, S. (2019) Localization of AMPA, kainate, and NMDA receptor mRNAs in the pigeon cerebellum. J. Chem. Neuroanat. 98, 71–79. <https://doi.org/10.1016/j.jchemneu.2019.04.004>
4. Bonifati, V., Fabrizio, E., Cipriani, R., Vanacore, N., Meco, G. (1994) Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 17(1), 73–82. <https://doi.org/10.1097/00002826-199402000-00008>
5. Boylan, K. (1990) Persistent dystonia associated with buspirone. Neurology 40(12), 1904. <https://doi.org/10.1212/WNL.40.12.1904>
6. Bristol-Myers Squibb Company (2001) BuSpar®. Available at: https://www.accessdata.fda.gov/drugsatfda _docs/label/2001/18731s39s45lbl.pdf
7. Brody, D., Adler, L. A., Kim, T., Angrist, B., Rotrosen, J. (1990) Effects of buspirone in seven schizophrenic subjects. J. Clin. Psychopharmacol. 10(1), 68–69. <https://doi.org/10.1097/00004714-199002000-00025>
8. Carter, C. J., Pycock, C. J. (1977) Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats [proceedings]. Br. J. Pharmacol. 60(2), 267P–268P.
9. Caviness, J. N., Brown, P. (2004) Myoclonus: Current concepts and recent advances. Lancet Neurol. 3(10), 598–607. <https://doi.org/10.1016/S1474-4422(04)00880-4>
10. Clay, P. G., Adams, M. M. (2003) Pseudo-Parkinson disease secondary to ritonavir-buspirone interaction. Ann. Pharmacother. 37(2), 202–205. <https://doi.org/10.1177/106002800303700207>
11. ClinCalc (2019) Top 300 Drugs. Available at: https://clincalc.com/DrugStats/Top300Drugs.aspx
12. Coulter, D. M., Pillans, P. I. (1995) Fluoxetine and extrapyramidal side effects. Am. J. Psychiatry 152(1), 122–125.
13. Dalley, J. W., Mar, A. C., Economidou, D., Robbins, T. W. (2008) Neurobehavioral mechanisms of impulsivity: Fronto-striatal systems and functional neurochemistry. Pharmacol. Biochem. Behav. 90(2), 250–260. <https://doi.org/10.1016/j.pbb.2007.12.021>
14. Eison, A. S., Temple, D. L. Jr. (1986) Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am. J. Med. 80(3B), 1–9. <https://doi.org/10.1016/0002-9343(86)90325-6>
15. Engberg, G. (1989) A metabolite of buspirone increases locus coeruleus activity via alpha 2-receptor blockade. J. Neural Transm. 76(2), 91–98. <https://doi.org/10.1007/BF01578749>
16. Floresco, S. B., Magyar, O. (2006) Mesocortical dopamine modulation of executive functions: beyond working memory. Psychopharmacology (Berl.) 188(4), 567–585. <https://doi.org/10.1007/s00213-006-0404-5>
17. Giménez-Roldán, S., Mateo, D., Muradas, V., De Yebenes, J. G. (1988) Clinical, biochemical, and pharmacological observation in a patient with postasphyxic myoclonus: association to serotonin hyperactivity. Clin. Neuropharmacol. 11(2), 151–160. <https://doi.org/10.1097/00002826-198804000-00006>
18. Goff, D. C., Midha, K. K., Brotman, A. W., McCormick, S., Waites, M., Amico, E. T. (1991) An open trial of buspirone added to neuroleptics in schizophrenic patients. J. Clin. Psychopharmacol. 11(3), 193–197.
19. Goldberg, R. J., Huk, M. (1992) Serotonin syndrome from trazodone and buspirone. Psychosomatics 33(2), 235–236. <https://doi.org/10.1016/S0033-3182(92)72007-6>
20. Griffith, J. D., Jasinski, D. R., Casten, G. P., McKinney, G. R. (1986) Investigation of the abuse liability of buspirone in alcohol-dependent patients. Am. J. Med. 80(3B), 30–35. <https://doi.org/10.1016/0002-9343(86)90329-3>
21. Haleem, D. J., Nawaz, S., Salman, T. (2018) Dose related effects of buspirone on pain, learning/memory and food intake. Regul. Toxicol. Pharmacol. 99, 182–190. <https://doi.org/10.1016/j.yrtph.2018.09.017>
22. Hammerstad, J. P., Carter, J., Nutt, J. G., Casten, G. C., Shrotriya, R. C., Alms, D. R., Temple, D. (1986) Buspirone in Parkinson’s disease. Clin. Neuropharmacol. 9(6), 556–560. <https://doi.org/10.1097/00002826-198612000-00007>
23. Howland, R. H. (2015) Buspirone: back to the future. J. Psychosoc. Nurs. Ment. Health Serv. 53(11), 21–24. <https://doi.org/10.3928/02793695-20151022-01>
24. Hurd, Y. L., Suzuki, M., Sedvall, G. C. (2001) D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain. J. Chem. Neuroanat. 22(1–2), 127–137. <https://doi.org/10.1016/S0891-0618(01)00122-3>
25. Jankovic, J., Tolosa, E. (2007) Parkinson’s Disease and Movement Disorders. Lippincott Williams and Wilkins, Philadelphia.
26. Jann, M. W., Froemming, J. H., Borison, R. L. (1990) Movement disorders and new azapirone anxiolytic drugs. J. Am. Board Fam. Pract. 3(2), 111–119.
27. Jansen, K. L. (1991) Buspirone and dystonia. Neurology 41(11), 1850, correspondence. <https://doi.org/10.1212/WNL.41.11.1850>
28. Jiménez-Jiménez, F. J. (1991) Buspirone and dystonia. Neurology 41(11), 1850, correspondence. <https://doi.org/10.1212/WNL.41.11.1850-a>
29. Jiménez-Jiménez, F. J., Garcia-Ruiz, P. J., Molina, J. A. (1997) Drug-induced movement disorders. Drug Saf. 16(3), 180–204. <https://doi.org/10.2165/00002018-199716030-00004>
30. Jiménez-Jiménez, F. J., Puertas, I., de Toledo-Heras, M. (2004) Drug-induced myoclonus: Frequency, mechanisms and management. CNS Drugs 18(2), 93–104. <https://doi.org/10.2165/00023210-200418020-00003>
31. Klawans, H. L. Jr., Goetz, C., Weiner, W. J. (1973) 5-hydroxytryptophan-induced myoclonus in guinea pigs and the possible role of serotonin in infantile myoclonus. Neurology 23(11), 1234–1240. <https://doi.org/10.1212/WNL.23.11.1234>
32. Kleedorfer, B., Lees, A. J., Stern, G. M. (1991) Buspirone in the treatment of levodopa induced dyskinesias. J. Neurol. Neurosurg. Psychiatry 54(4), 376–377. <https://doi.org/10.1136/jnnp.54.4.376-a>
33. Korsgaard, S., Gerlach, J., Christensson, E. (1985) Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur. J. Pharmacol. 118(3), 245–252. <https://doi.org/10.1016/0014-2999(85)90135-9>
34. Lepping, P., Delieu, J., Mellor, R., Williams, J. H. H., Hudson, P. R., Hunter-Lavin, C. (2011) Antipsychotic medication and oxidative cell stress: a systematic review. J. Clin. Psychiatry 72(3), 273–285. <https://doi.org/10.4088/JCP.09r05268yel>
35. LeWitt, P. A., Walters, A., Hening, W., McHale, D. (1993) Persistent movement disorders induced by buspirone. Mov. Disord. 8(3), 331–334. <https://doi.org/10.1002/mds.870080313>
36. Liegghio, N. E., Yeragani, V. K., Moore, N. C. (1988) Buspirone-induced jitteriness in three patients with panic disorder and one patient with generalized anxiety disorder. J. Clin. Psychiatry 49(4), 165–166.
37. Loane, C., Politis, M. (2012) Buspirone: what is it all about? Brain Res. 1461, 111–118. <https://doi.org/10.1016/j.brainres.2012.04.032>
38. López-Sendón, J., Mena, M. A., de Yébenes, J. G. (2013) Drug-induced Parkinsonism. Expert Opin. Drug Saf. 12(4), 487–496. <https://doi.org/10.1517/14740338.2013.787065>
39. Ludwig, C. L., Weinberger, D. R., Bruno, G., Gillespie, M., Bakker, K., LeWitt, P. A., Chase, T. N. (1986) Buspirone, Parkinson’s disease, and the locus ceruleus. Clin. Neuropharmacol. 9(4), 373–378. <https://doi.org/10.1097/00002826-198608000-00004>
40. Lydiard, R. (1989) Buspirone revisited. J. Clin. Psychiatry 50(8), 308–308.
41. Manos, G. H. (2000) Possible serotonin syndrome associated with buspirone added to fluoxetine. Ann. Pharmacother. 34(7–8), 871–874. <https://doi.org/10.1345/aph.19341>
42. McMillen, B. A., Matthews, R. T., Sanghera, M. K., Shepard, P. D., German, D. C. (1983) Dopamine receptor antagonism by the novel antianxiety drug, buspirone. J. Neurosci. 3(4), 733–738. <https://doi.org/10.1523/JNEUROSCI.03-04-00733.1983>
43. Mejia, N. I., Jankovic, J. (2005) Secondary tics and tourettism. Braz. J. Psychiatry 27(1), 11–17. <https://doi.org/10.1590/S1516-44462005000100006>
44. Metz, A. (1990) Interaction between fluoxetine and buspirone. Can. J. Psychiatry 35(8), 722–723. <https://doi.org/10.1177/070674379003500823>
45. Mohajjel Nayebi, A. A., Sheidaei, H. (2010) Buspirone improves haloperidol-induced Parkinson disease in mice through 5-HT(1A) recaptors. Daru 18(1), 41–45.
46. Naber, D., Weinberger, D. R., Gillespie, M., Chase, T. N. (1992) Failure of buspirone and verapamil to improve spasmodic torticollis. J. Neuropsychiatry Clin. Neurosci. 4(1), 82–84.
47. Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., Greenblatt, D. J. (1981) A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30(2), 239–245. <https://doi.org/10.1038/clpt.1981.154>
48. Newton, R. E., Marunycz, J. D., Alderdice, M. T., Napoliello, M. J. (1986) Review of the side-effect profile of buspirone. Am. J. Med. 80(3B), 17–21. <https://doi.org/10.1016/0002-9343(86)90327-X>
49. Paquette, M. A., Foley, K., Brudney, E. G., Meshul, C. K., Johnson, S. W., Berger, S. P. (2009) The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635 -sensitive mechanism. Psychopharmacology (Berl.) 204(4), 743–754. <https://doi.org/10.1007/s00213-009-1505-8>
50. Patterson, J. F. (1988) Akathisia associated with buspirone. J. Clin. Psychopharmacol. 8(4), 296–297. <https://doi.org/10.1097/00004714-198808000-00026>
51. Poyurovsky, M., Weizman, A. (1997) Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin. Int. Clin. Psychopharmacol. 12(5), 263–268. <https://doi.org/10.1097/00004850-199709000-00003>
52. Pranzatelli, M. R., Franz, D., Tate, E., Martens, J. M. (1993) Buspirone in progressive myoclonus epilepsy. J. Neurol. Neurosurg. Psychiatry 56(1), 114–115. <https://doi.org/10.1136/jnnp.56.1.114>
53. Richter, A., Löscher, W. (1995) Behavioural response to pharmacologic manipulation of serotonin receptors in the genetically dystonic hamster. Pharmacol. Biochem. Behav. 52(4), 655–665. <https://doi.org/10.1016/0091-3057(95)00162-P>
54. Ritchie, E. C., Bridenbaugh, R. H., Jabbari, B. (1988) Acute generalized myoclonus following buspirone administration. J. Clin. Psychiatry 49(6), 242–243.
55. Rock, N. L. (1990) Possible adverse effects of buspirone when used with other psychotropic drugs. J. Clin. Psychopharmacol. 10(5), 380–381. <https://doi.org/10.1097/00004714-199010000-00028>
56. Scholtissen, B., Verhey, F. R. J., Adam, J. J., Weber, W., Leentjens, A. F. G. (2006) Challenging the serotonergic system in Parkinson disease patients: Effects on cognition, mood, and motor performance. Clin. Neuropharmacol. 29(5), 276–285. <https://doi.org/10.1097/01.WNF.0000229013.95927.C7>
57. Shireen, E. (2016) Experimental treatment of antipsychotic-induced movement disorders. J. Exp. Pharmacol. 8, 1–10. <https://doi.org/10.2147/JEP.S63553>
58. Smith, J. M., Baldessarini, R. J. (1980) Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch. Gen. Psychiatry 37(12), 1368–1373. <https://doi.org/10.1001/archpsyc.1980.01780250054006>
59. Sokoloff, P., Le Foll, B. (2017) The dopamine D3 receptor, a quarter century later. Eur. J. Neurosci. 45(1), 2–19. <https://doi.org/10.1111/ejn.13390>
60. Strauss, A. (1988) Oral dyskinesia associated with buspirone use in an elderly woman. J. Clin. Psychiatry 49(8), 322–323.
61. Swett, C. Jr. (1975) Drug-induced dystonia. Am. J. Psychiatry 132(5), 532–534.
62. Taylor, D. P. (1988) Buspirone, a new approach to the treatment of anxiety. FASEB J. 2(9), 2445–2452. <https://doi.org/10.1096/fasebj.2.9.2836252>
63. Tompins, E., Clemento, A., Taylor, D. P., Perhach, J. (1980) Inhibition of aggressive behavior in rhesus monkeys by buspirone. Res. Commun. Psychol. Psychiatr. Behav. 5(4), 337–352.
64. Wilson, T. K., Tripp, J. (2019) Buspirone. StatPearls [Internet], StatPearls Publishing, Treasure Island.
65. Zhai, S., Tanimura, A., Graves, S. M., Shen, W., Surmeier, D. J. (2018) Striatal synapses, circuits, and Parkinson’s disease. Curr. Opin. Neurobiol. 48, 9–16. <https://doi.org/10.1016/j.conb.2017.08.004>
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)

Archive